Abaxis, Inc. (NASDAQ:ABAX)

Low debt, lots of cash, growing business. High p/e, but i would pay a premium for growth.

wow.....if they can crack this market it will change how we visit doctors and become a must have for ever doctor. Will it be bought out for a hige premium ?

Solid Balance sheet with no debt which I love.

Pretty solid looking balance sheet. No debt, and revenue growth is great. My only concern is that despite huge revenue growth, earnings haven't progressed as steadily: SGA is growing along with overall operating expenses which is cutting into profits quite a bit. However, they are putting more money into their R&D which should help out in the long run.

Pros again, no debt, great revenue growth. Another plus is their cash flow from operating activities is growing. Get SGA under control and cut operating costs and I think this small cap stock will do just fine.

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision
and accuracy equivalent to a clinical laboratory analyzer.
6/30/09 Quarterly highlights include:
-- Revenues of $29.6 million, up 21% over last year's comparable
quarter.
-- Veterinary market sales of $21.8 million, up 31% over last year's
comparable quarter.
-- North America revenues of $24.1 million, up 19% over last year's
comparable quarter.
-- International revenues of $5.5 million, up 29% over last year's
comparable quarter.
-- Medical and veterinary reagent disc sales of $18.4 million, up 31% over
last year's comparable quarter.
-- Gross profit of $17.2 million, up 27% over last year's comparable
quarter.
-- Operating income of $5.7 million, up 42% over last year's
comparable quarter.

-- Net income of $3.8 million, up 35% over last year's comparable
quarter.

Healthcare spending is going up, in part because of healthcare reform. Rising on 5 times average volume. Q2 profit soared.

I gained 52% (october 2008 - march 2009). A good stock. At least in this kind of market.

Abaxis Inc is a medical equipment company that sells Piccolo blood test machines. The company has greatly increased numbers and created long term contracts through point of sale. The company sells its machines primarily in the United States and also has a presence in Japan through a distribution deal.

According to the October 29th issue of Forbes magazine the company closed deals with 60% of MDs that it attempted to sell to. The Piccolo machines sell for $15,000 and use discs exclusively sold by Abaxis which provides a nice revenue stream. The number of offices with the machine was at .2% in this article. At the time of publication the company was just entering the veterinary field as well.

Forbes named Abaxis #11 in its annual best small companies in 2007. Previously in 2006 the company was listed at 25. Perhaps the biggest honor was Abaxis's CEO named entrepreneur of the year by Forbes for 2007.

Abaxis has a market cap of between $500 million and $750 million currently which makes it a growing small cap with plenty of room to grow. The company has no debt on its books. The company is represented in the S&P 600 Smallcap and S&P 1500 Supercomp.

A new machine was launched in September of 2007 called the HM5. The company just announced record sales for both the 3rd and 4th quarters of fiscal 2008. The discs used for the machines are being sold at a higher price and are recognized at a lower cost to make which will increase profit margins over the next year substantially. International sales make up 16% of the company's sales.

Abaxis sold 32 instruments at the North American Veterinarian Conference. The company sold 105 Piccolo human blood test machines in the month of Decmeber 2007. Eight hundred and eighty instruments total in the third quarter of 2008 and has the capacity to make 1000 instruments a quarter now and an unlimited potential with the addition of new vendors according to the conference call for the third quarter.

The company said they had a goal of $1 per share in earnings for fiscal 2008. I see them exceeding this and creating great shareholder value by producing more disks and tapping the international market. They also had announced that they planned to explore heartworm tests on animals using their machines. Shares have been as high as $40 the past 52 weeks. The shares are currently at $29.41 in after hours trading. I have a price target of $45 by 07/01/10.

Please check out my blog at:

http://stockworldpicks.blogspot.com

Serves both lower cost clinics with blood testing equipment and also pets/veteranarian market with similar products. Razor/razor blade model as blood reagent sales exceed machine sales, and each new customer sets up profitable long term repeat business. Highest profit segment now growing fastest. Also provides more tests faster and cheaper than

This is a good trading stock with very good fundamentals behind it. It has started an upward movement from $22 and I am watching the technicals to make sure there is some momentum behind this move. Beta is 1.45 so it can get some good moves with the market. Looking for it to go back to the 52 week high of $40.

Testing a portfolio of companies that start with the letter "A".

Abaxis has a solid niche in the veterinary point-of-care diagnostics business augmented by an open-ended growth opportunity in human point-of-care diagnostics thanks to its unique Piccolo Xpress machine. The business model is classic razor-and-blade, with the machines (razors) selling at about a 50% gross margin, while the routers (blades) sell for closer to a 70% GM. There remains room for expansion of GMs, primarily on the router side, and new distribution contracts should improve volumes, along with CLIA waivers for multiple diagnostic tests.

One thing I have learned is don't argue with the market. This stock is heavily owned by institutions and it appears that they want to buy more. It has a huge growth potential both in America and the rest of the world.

Price above all moving average lines.

All the hard work is done, soon it should be all in the FDA's hands. When approved cash flow will be the name of the game for this small company.

Good growth and earnings.

I like this stock and my target is $40

Better than BABY

THE NEED FOR QUICKER MEDICAL DIAGNOSIS